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Human Rhinovirus Inhibits Macrophage Phagocytosis of Bacteria in
Chronic Obstructive Pulmonary Disease
More Than a Common Cold
Chronic obstructive pulmonary disease (COPD) results from
chronic inﬂammation, tissue injury, and aberrant repair processes
in the respiratory airways. Acute viral and/or bacterial infections
cause acute exacerbations. Rhinovirus (RV) infection is the
most common viral cause of acute exacerbations in COPD,
accounting for approximately 60% of viral acute exacerbations
(1). Secondary bacterial infections frequently follow viral
infection, resulting in more severe clinical illness with a
greater reduction in FEV1 over FVC and greater length of
hospitalization (2).
In this issue of the Journal, Finney and colleagues (pp.
1496–1507) provide an important advance by demonstrating
that a type A human RV (HRV) infection, HRV16, impairs
phagocytosis of two important pathogens in COPD:
nontypeable Haemophilus inﬂuenzae (NTHi) and Streptococcus
pneumoniae (3). The HRV-associated phagocytic defect was
demonstrated for both bacteria in the case of monocyte-derived
macrophages (MDMs), but only for NTHi in the case of
alveolar macrophages (AMs). Of note, the authors were able to
demonstrate viral uptake by AMs challenged ex vivo, with
cytoplasmic localization of virions. The phagocytic defect
was reprised with a Toll-like receptor 3 (TLR3) agonist
(polyinosinic:polycytidylic acid) and was a delayed response,
requiring approximately 6 hours of HRV incubation. The
authors also showed that HRV16 decreased proinﬂammatory
cytokines in COPD MDMs challenged with NTHi. MDMs
and AMs from subjects with COPD showed reduced
phagocytosis to NTHi and S. pneumoniae (in the absence of
HRV challenge) as compared with those obtained from healthy
donors, and the degree of AM phagocytosis was correlated with
MDM phagocytosis and with FEV1% predicted for both
pathogens.
Other models of the interaction between HRV and
macrophages are of potential interest. HRV also induces
replication-independent activation of TLR2 in mouse
macrophages with production of proinﬂammatory cytokines (4).
Conversely, HRV1B reduces CXCL8 (C-X-C motif chemokine
ligand 8) production in response to NTHi, with reduced bacterial
clearance and prolonged neutrophilic inﬂammation in
mouse lungs (5). In this case, replication-independent viral
responses induce degradation of IRAK-1 (IL-1 receptor–associated
kinase 1), a key adaptor required for MyD88-dependent
TLR signaling, inducing tolerance to bacterial stimuli in
AMs.
The data add to the range of viral infections that have
been shown to alter macrophage phagocytosis of bacteria,
including inﬂuenza A virus (6) and HIV-1 infection (7).
Whether HRV can replicate in macrophages has been a
subject of controversy. Viable virus was detected in MDMs,
but only in one in a thousand cells (8). Detection of viable
HRV16 in AMs infected ex vivo dropped to almost zero within
48 hours (9). In contrast, HRV16 RNA has been detected up
to 10 days after infection of AMs. In the study by Finney
and colleagues, a TLR3 agonist also inhibited phagocytosis,
suggesting that a delayed pattern recognition receptor–mediated
response could mediate the defect. Although cytoplasmic
localization was described, it is of interest that there was no
nuclear localization; therefore, the virologic mechanisms
remain incompletely deﬁned. In addition, the basis for a
selective effect on COPD macrophages but not healthy
macrophages is unclear.
The authors previously described a systemic
macrophage phagocytic COPD defect inMDMswhose development
is independent of the unique environment of the COPD lung (10).
This is in contrast to other reports that suggested phagocytic
defects for NTHi in AMs, but not in MDMs (11). The authors
suggest that this discrepancy may be ascribed to differences in the
use of colony factors in MDM cultures. However, differences
among assays are also likely to contribute, with some measuring
uptake of heat-killed unopsonized bacteria (3, 10) and others
measuring uptake of live bacteria with or without opsonization (11,
12). Although most studies have reported reduced S. pneumoniae
ingestion (3, 10, 12), Berenson and colleagues did not describe
impaired phagocytosis of S. pneumoniae in AMs; however, to
counteract autolysis in bacterial cultures, the authors elected to
study bacteria in stationary rather than mid-log phase growth (13).
Of note, Berenson and colleagues assessed phagocytosis by AMs as
the percentage of cells ingesting bacteria, rather than a measure
of total bacterial uptake in the population. Because most studies
have shown that only a subset of macrophages in culture ingest
bacteria, this suggests that it may be the level of ingestion by this
population that changes rather than the spectrum of cells within a
quite heterogeneous population of cells that ingest bacteria.
Collectively, these studies suggest that there is a systemic phagocytic
defect of bacteria (but not inert particles such as latex beads)
compounded by environmental inﬂuences, including HRV infection.
Finney and colleagues also found that in patients with mild to
moderate COPD, results obtained with MDMs correlated with the
degree of AM deﬁcit. The validity of using MDMs to study AMs
has long been debated. Recent lineage-tracing experiments suggest
that in mice, AMs are derived from embryonic hematopoietic
stem cells in the fetal liver and maintained in steady state
independently of blood monocytes (14). This emphasizes the
importance of validating MDM ﬁndings in AMs, as Finney and
her team have done. However, the origin of AM populations in
the human lung during COPD is still debated. Moreover, the
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plasticity of macrophages cultured outside their environmental
niche means that even ex vivo studies of human AMs have
limitations that may only be resolved in tissue culture models,
ex vivo ventilated human lungs, or, ultimately, experimental
human challenge models.
What are the major implications of this study
for patients living with COPD? Conventional teaching
has suggested that respiratory tract infections are the
result of individual pathogens, usually recently acquired.
However, microbiome studies suggest a more complex interplay
between pathogens, and that infections result from “dysbiosis,”
which is often triggered by viral infections. Dysbiosis with
broad population-level changes in bacteria is also observed
during acute exacerbations in COPD (15). The effects of
multipathogen exposure on the phagocytic function of
macrophages should be considered. In this regard, the study by
Finney and colleagues suggests that HRV could contribute to
dysbiosis of the lung microbiome through the phagocytic
defect described, thereby promoting acute exacerbations or
episodes of community-acquired pneumonia. Therapeutic
approaches will need to address ways in which the
host response can be recalibrated during these infections
and the (as yet unidentiﬁed) mechanistic basis of the
phagocytic defect can be corrected. This will potentially
require early detection of viral respiratory tract infections,
as well as targeted interventions to correct the host
defect. n
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